On Monday, Shares of Regions Financial Corp (NYSE:RF), added 0.51% and closed at $9.92 in the last trading session. The last trading range of the stock ranges between $9.78 and $9.94. Regions Financial Corporation, together with its auxiliaries, provides banking and bank-related services to individual and corporate customers in the United States. Its Corporate Bank segment offers commercial banking services, such as commercial and industrial, commercial real estate, and shareholder real estate lending, in addition to equipment lease financing services. This segment serves corporate, middle market, small business, and commercial real estate developers and shareholders. The companys Consumer Bank segment provides consumer banking products and services related to residential first mortgages, home equity lines and loans, small business loans, indirect loans, consumer credit cards, and other consumer loans, in addition to the corresponding deposit relationships. Its Wealth Administration segment offers wealth administration products and services, counting credit related products, trust and investment administration, asset administration, retirement and savings solutions, estate planning, and personal and commercial insurance products to individuals, businesses, governmental institutions, and non-profit entities.
Valero Energy Corporation (NYSE:VLO), DROPPED -0.19% and closed at $52.90 in the last trading session. The last trading range of the stock ranges between $52.51 and $53.25. The company’s Market capitalization is $25.01 Billion with the total Outstanding Shares of 461.34 Million. Valero Energy Corporation (VLO) recently declared that it will host a conference call on October 25, 2016 at 11:00 a.m. ET to discuss third quarter earnings results, which will be released earlier that day, and provide an update on company operations.
Depomed Inc (NASDAQ:DEPO), gained 2.36% and closed at $25.58 in the last trading session. The last trading range of the stock ranges between $24.73 and $25.62. During the 52-week trading session the minimum price at which share price traded, registered at $12.25 and reached to max level of $27.02. Depomed, Inc. (DEPO) recently declared that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in favor of Depomed in the company’s patent litigation against all three filers of Abbreviated New Drug Applications (ANDAs) for Depomed’s NUCYNTA franchise. With the court’s ruling, Depomed anticipates market exclusivity until December 2025 for NUCYNTA® ER, NUCYNTA® and NUCYNTA® oral solution (an unmarketed form of NUCYNTA). 1
“We are happy with the Court’s decision as it confirms the validity and strength of the NUCYNTA patents,” said Jim Schoeneck, President and CEO of Depomed. “We look forward to growing the NUCYNTA franchise, comprised of two important and highly-differentiated medicines, for at least the next 9 years.”
The court found U.S. patent Nos. 7,994,364 and RE39,593 to be valid and infringed by the defendants. The patents cover the entire NUCYNTA franchise and will expire on December 27, 2025 and February 5, 2023, respectively.1 Judge Cecchi upheld the validity of U.S. Patent No. 8,536,130 (the “130 Patent”), but found that two of the three filers do not infringe the patent. The ‘130 Patent covers NUCYNTA ER until March 2029. 1 The company intends to appeal the court’s finding as it relates to infringement of the ‘130 Patent.